Similar articles for PMID: 33104316

Year	Number of Results
1997	2
1999	3
2000	1
2001	7
2002	5
2003	5
2004	16
2005	4
2006	22
2007	8
2008	2
2009	1
2010	1
2011	1
2012	3
2013	1
2016	1
2017	1
2018	3
2019	7
2020	5
2021	3
2022	4
2023	1
2024	3
2025	1

1

[No authors listed] [No authors listed] 2020 Oct 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Oct 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33104316 Free Books & Documents. Review.

2

Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.

Wagstaff AJ, Frampton JE, Croom KF. Wagstaff AJ, et al. Drugs. 2003;63(11):1101-20. doi: 10.2165/00003495-200363110-00013. Drugs. 2003. PMID: 12749744 Review.

3

Tegaserod for the Treatment of Irritable Bowel Syndrome.

Madia VN, Messore A, Saccoliti F, Tudino V, De Leo A, De Vita D, Bortolami M, Scipione L, Pindinello I, Costi R, Di Santo R. Madia VN, et al. Antiinflamm Antiallergy Agents Med Chem. 2020;19(4):342-369. doi: 10.2174/1871523018666190911121306. Antiinflamm Antiallergy Agents Med Chem. 2020. PMID: 31518227 Free PMC article. Review.

4

Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2.

Wang Z, Chen Y, Li X, Zhang Y, Zhao X, Zhou H, Lu X, Zhao L, Yuan Q, Shi Y, Zhao J, Dong Z, Jiang Y, Liu K. Wang Z, et al. Cancers (Basel). 2022 Jul 23;14(15):3592. doi: 10.3390/cancers14153592. Cancers (Basel). 2022. PMID: 35892850 Free PMC article.

5

Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).

Appel-Dingemanse S, Hirschberg Y, Osborne S, Pommier F, McLeod J. Appel-Dingemanse S, et al. Eur J Clin Pharmacol. 2001 Mar;56(12):889-91. doi: 10.1007/s002280000239. Eur J Clin Pharmacol. 2001. PMID: 11317476 Clinical Trial.

6

Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.

Rivkin A. Rivkin A. Clin Ther. 2003 Jul;25(7):1952-74. doi: 10.1016/s0149-2918(03)80198-4. Clin Ther. 2003. PMID: 12946544 Review.

7

Zelmac (Novartis AG).

Norman P. Norman P. IDrugs. 1999 Mar;2(3):265-9. IDrugs. 1999. PMID: 16160939

8

Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit.

Appel S, Kumle A, Meier R. Appel S, et al. Clin Pharmacol Ther. 1997 Nov;62(5):546-55. doi: 10.1016/S0009-9236(97)90050-3. Clin Pharmacol Ther. 1997. PMID: 9390111 Clinical Trial.

9

The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.

Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. Kahrilas PJ, et al. Aliment Pharmacol Ther. 2000 Nov;14(11):1503-9. doi: 10.1046/j.1365-2036.2000.00854.x. Aliment Pharmacol Ther. 2000. PMID: 11069322 Clinical Trial.

10

Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.

Liu W, Stachura P, Xu HC, Umesh Ganesh N, Cox F, Wang R, Lang KS, Gopalakrishnan J, Häussinger D, Homey B, Lang PA, Pandyra AA. Liu W, et al. J Exp Clin Cancer Res. 2020 Feb 21;39(1):38. doi: 10.1186/s13046-020-1539-7. J Exp Clin Cancer Res. 2020. PMID: 32085796 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 33104316

90 results

Results by year